Clovis Oncology, Inc. Net Change in Cash
Clovis Oncology, Inc. reported Net Change in Cash of -$85.11 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2022-11-09
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$21.19M.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$49.31M, a 3440.58% decline year-over-year.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $1.48M.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2019-03-31 was -$98.57M.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was -$96.80M, a 223.48% decline from fiscal 2020.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $78.40M.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$60.04M.
- Clovis Oncology, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2018 was -$242.32M, a 197.71% decline from fiscal 2017.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$85.11M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | -$48.85M 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | -$21.19M 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$96.80M 10-K · filed 2022-02-24 | |||
| 2021-09-30 | -$68.28M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$10.03M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$49.31M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $78.40M 10-K · filed 2022-02-24 | |||
| 2020-09-30 | $62.87M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $99.60M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $1.48M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$60.04M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$20.39M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$113.27M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | -$98.57M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | -$242.32M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$173.34M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $4.12M 10-Q · filed 2019-08-02 | |||
| 2018-03-31 | -$90.08M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $248.01M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $395.29M 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | $275.60M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | -$62.57M 10-K · filed 2019-02-28 |